Alector, Inc. (ALEC)
NASDAQ: ALEC · IEX Real-Time Price · USD
5.83
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Alector Revenue
Alector had revenue of $96.41M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $15.89M. In the year 2023, Alector had annual revenue of $97.06M.
Revenue (ttm)
$96.41M
Revenue Growth
-23.30%
P/S Ratio
5.83
Revenue / Employee
$395,107
Employees
244
Market Cap
561.92M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
| Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
| Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
| Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
| Dec 31, 2019 | 21.22M | -6.46M | -23.33% |
| Dec 31, 2018 | 27.68M | 23.94M | 641.02% |
| Dec 31, 2017 | 3.74M | 3.32M | 797.84% |
| Dec 31, 2016 | 416.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 280.83M |
| Castle Biosciences | 250.73M |
| National Research | 147.42M |
| Quanterix | 125.98M |
| IRadimed | 67.69M |
| Verve Therapeutics | 16.05M |
ALEC News
- 6 weeks ago - Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform - GlobeNewsWire
- 2 months ago - Alector to Participate in Upcoming Healthcare Conferences - GlobeNewsWire
- 5 months ago - Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call - GlobeNewsWire
- 5 months ago - Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease - GlobeNewsWire
- 5 months ago - FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) - GlobeNewsWire
- 6 months ago - Alector Announces Closing of Public Offering - GlobeNewsWire
- 6 months ago - Alector Announces Pricing of Public Offering of Common Stock - GlobeNewsWire